Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: From the bench to clinical application

Cancer Gene Therapy

Volumn 20, Issue 11, 2013, Pages 599-605

  Tanemura, A ^a   Kiyohara, E ^a   Katayama, I ^a   Kaneda, Y ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

antitumor effect; HVJ E; malignant melanoma

Indexed keywords

HVJ ENVELOPE VECTOR; INTERLEUKIN 12; INTERLEUKIN 6; ONCOLYTIC VIRUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CYTOKINE RELEASE; GROWTH INHIBITION; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; LUNG METASTASIS; MEDIATOR; MELANOMA; MELANOMA CELL; MICROARRAY ANALYSIS; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SENDAI VIRUS; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; UNIVERSITY HOSPITAL; VIRAL GENE DELIVERY SYSTEM; VIRUS HEMAGGLUTINATION;

MUS; SENDAI VIRUS;

ANIMALS; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; MELANOMA; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; SENDAI VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84888379835     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.61     Document Type: Review

References (31)

1. Lens MB, Eisen TG. Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin Pharmacother 2003; 4: 2205-2211.
2. Li Y, McClay EF. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002; 29: 413-426.
3. Ridolfi R, Petrini M, Fiammenghi L, Stefanelli M, Ridolfi L, Ballardini M et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006; 4: 36.
4. Wei Y, Sticca RP, Holmes LM, Burgin KE, Li J, Williamson J et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 2006; 28: 585-593.
5. Goto S, Kaneko T, Miyamoto Y, Eriguchi M, Kato A, Akeyama T et al. Combined immunocell therapy using activated lymphocytes and monocyte-derived dendritic cells for malignant melanoma. Anticancer Res 2005; 25: 3741-3746.
6. Homma S, Kikuchi T, Ishiji N, Ochiai K, Takeyama H, Saotome H et al. Cancer immunotherapy by fusions of dendritic and tumor cells and rh-IL-12. Eur J Clin Invest 2005; 35: 279-286.
7. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1900.
8. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM et al. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res 2003; 9: 2973-2980.
9. Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. Nat Rev Clin Oncol 2011; 8: 577-585.
10. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26: 5233-5239.
11. Hodi FS, O'day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 368: 711-723.
12. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1: 1223-1225.
13. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999; 5: 298-303.
14. Kaneda Y. A non-replicating oncolytic vector as a novel therapeutic tool against cancer. BMB Rep 2010; 43: 773-780.
15. Kaneda Y. Virosome: a novel vector to enable multi-modal strategies for cancer therapy. Adv Drug Deliv Rev 2012; 64: 730-738.
16. Kurooka M, Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res 2007; 67: 227-236.
17. Okada Y. Sendai virus-induced cell fusion. Methods Enzymol 1993; 221: 18-41.
18. Kaneda Y. Applications of hemagglutinating virus of Japan in therapeutic delivery systems. Expert Opin Drug Deliv 2008; 5: 221-233.
19. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
20. Jami J, Grandchamp S. Karyological properties of human-mouse somatic hybrids. Proc Natl Acad Sci USA 1971; 68: 3097-3101.
21. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53: 307-332.
22. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002; 6: 219-226.
23. Fujiwara A, Kurooka M, Miki T, Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol Immunother 2008; 57: 73-84.
24. Powrie F, Maloy KJ. Regulating the regulators. Science 2003; 299: 1030-1031.
25. Fehervari Z, Sakaguchi S. Control of Foxp3+CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol 2004; 16: 1769-1780.
26. Wan S, Xia C, Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 2007; 178: 271-279.
27. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol 2001; Chapter 20: Unit 20.1.
28. Ruiter DJ, Bergman W, Welvaart K, Scheffer E, van Vloten WA, Russo C et al. Immunohistochemical analysis of malignant melanomas and nevocellular nevi with monoclonal antibodies to distinct monomorphic determinants of HLA antigens. Cancer Res 1984; 44: 3930-3935.
29. Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert J, Desbois M et al. Cancerinduced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res 2012; 72: 2757-2767.
30. Kaneda Y, Yamamoto S, Nakajima T. Development of HVJ envelope vector and its application to gene therapy. Adv Genet 2005; 53: 303-332.
31. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.